Literature DB >> 15630411

Origins of leukaemia in children with Down syndrome.

Johann K Hitzler1, Alvin Zipursky.   

Abstract

Transient megakaryoblastic leukaemia is found in 10% of newborns with Down syndrome, characterized by constitutional trisomy 21. Although in most cases the leukaemic cells disappear spontaneously after the first months of life, irreversible acute megakaryoblastic leukaemia develops in 20% of these individuals within 4 years. The leukaemic cells typically harbour somatic mutations of the gene encoding GATA1, an essential transcriptional regulator of normal megakaryocytic differentiation. Leukaemia that specifically arises in the context of constitutional trisomy 21 and somatic GATA1 mutations is a unique biological model of the incremental process of leukaemic transformation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15630411     DOI: 10.1038/nrc1525

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  46 in total

1.  Low frequency of type-I and type-II aberrations in myeloid leukemia of Down syndrome, underscoring the unique entity of this disease.

Authors:  Marjolein Blink; Marry M van den Heuvel-Eibrink; Valerie de Haas; Jan-Henning Klusmann; Henrik Hasle; C Michel Zwaan
Journal:  Haematologica       Date:  2012-04       Impact factor: 9.941

Review 2.  Using genomics to define pediatric blood cancers and inform practice.

Authors:  Rachel E Rau; Mignon L Loh
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

3.  Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling.

Authors:  Jean-Pierre Bourquin; Aravind Subramanian; Claudia Langebrake; Dirk Reinhardt; Olivier Bernard; Paola Ballerini; André Baruchel; Hélène Cavé; Nicole Dastugue; Henrik Hasle; Gertjan L Kaspers; Michel Lessard; Lucienne Michaux; Paresh Vyas; Elisabeth van Wering; Christian M Zwaan; Todd R Golub; Stuart H Orkin
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-21       Impact factor: 11.205

4.  GATA1 mutations in a cohort of Malaysian children with Down syndrome-associated myeloid disorder.

Authors:  Su Han Lum; Soo Sin Choong; Shekhar Krishnan; Zulqarnain Mohamed; Hany Ariffin
Journal:  Singapore Med J       Date:  2016-06       Impact factor: 1.858

5.  Down syndrome and microRNAs.

Authors:  Aldina Brás; António S Rodrigues; Bruno Gomes; José Rueff
Journal:  Biomed Rep       Date:  2017-11-17

Review 6.  Down syndrome and the complexity of genome dosage imbalance.

Authors:  Stylianos E Antonarakis
Journal:  Nat Rev Genet       Date:  2016-12-28       Impact factor: 53.242

7.  Myeloid Proliferations Associated with Down Syndrome.

Authors:  Alan B Cantor
Journal:  J Hematop       Date:  2014-12-14       Impact factor: 0.196

8.  Trisomy 21 enhances human fetal erythro-megakaryocytic development.

Authors:  Stella T Chou; Joanna B Opalinska; Yu Yao; Myriam A Fernandes; Anna Kalota; John S J Brooks; John K Choi; Alan M Gewirtz; Gwenn-ael Danet-Desnoyers; Richard L Nemiroff; Mitchell J Weiss
Journal:  Blood       Date:  2008-09-23       Impact factor: 22.113

9.  Xenopus meiotic microtubule-associated interactome.

Authors:  Vincent Gache; Patrice Waridel; Christof Winter; Aurelie Juhem; Michael Schroeder; Andrej Shevchenko; Andrei V Popov
Journal:  PLoS One       Date:  2010-02-17       Impact factor: 3.240

10.  Gene profiling of the erythro- and megakaryoblastic leukaemias induced by the Graffi murine retrovirus.

Authors:  Veronique Voisin; Philippe Legault; Diana Paulina Salazar Ospina; Yaacov Ben-David; Eric Rassart
Journal:  BMC Med Genomics       Date:  2010-01-26       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.